Short answer
Moderna (MRNA) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 3.02 (Unregistered Sales of Equity Securities). $3.0B zero-coupon convertible debt due March 2032, providing substantial funding without regular cash interest.
Moderna 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $3.0B zero-coupon convertible debt due March 2032, providing substantial funding without regular cash interest
- Net proceeds $2,957.3M, including $328.8M for capped calls and remaining funds for oncology investment or debt repayment
- Initial conversion price $210.58, a 47.5% premium to Moderna’s $142.77 share price, limiting near-term dilution risk
- Capped calls cover underlying shares, reducing conversion dilution or excess-cash payments up to a $392.62 cap price
- Redemption unavailable before September 6, 2029, while conversion could create dilution if shares exceed conversion thresholds
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 points investors to Item 1.01 for details of any newly created direct financial obligation
- Financial impact depends on the referenced agreement’s payment obligations, timing, and counterparty terms
Item 3.02 · Unregistered Sales of Equity Securities
- Convertible notes sold privately under Section 4(a)(2) and Rule 144A, limiting immediate public trading
- Initial conversion potential: 14,246,100 common shares
- Maximum conversion potential: 21,012,600 shares in limited circumstances
- Potential dilution to existing shareholders, subject to customary anti-dilution adjustments
- No resale registration statement planned for the notes or conversion shares
Item 8.01 · Other Events
- Moderna announced a proposed offering on August 27, 2026, followed by pricing of the Notes on August 28, 2026
- Debt issuance creates financing obligations and potential interest expense, with terms detailed in Exhibits 99.1 and 99.2
- Anticipated use of proceeds is forward-looking and subject to execution, operating needs, and disclosed risk factors
- Investors should review Exhibits 99.1 and 99.2 for offering size, pricing, maturity, interest rate, and proceeds allocation
Item EX-99.1 · Exhibit EX-99.1
- Proposed $2.0B convertible senior notes due 2032, with initial purchasers’ option for an additional $300M
- Zero regular interest and no principal accretion, limiting near-term cash interest expense
- Proceeds targeted toward oncology investment, debt repayment, and capped-call transaction costs
- Convertible settlement may include cash, Moderna shares, or both, creating potential equity dilution
- Capped-call hedge targets dilution offset up to a cap initially at least 150% above pricing-date stock price
Item EX-99.2 · Exhibit EX-99.2
- $2.6B upsized convertible notes due 2032, providing substantial funding for oncology investment and debt repayment
- 0.00% coupon, approximately $2.563B net proceeds after fees and capped-call costs
- Initial conversion price $210.58, a 47.5% premium to Moderna’s $142.77 share price
- Approximately $285.0M capped-call cost, with a $392.6175 cap price intended to reduce conversion dilution
- Potential future dilution remains, with additional $400.0M notes available under the initial purchasers’ option
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Moderna 8-K filings
Get the next MRNA 8-K as it lands
Follow MRNA for push alerts, or ask the research agent what this filing means.